|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
CA1276103C
(en)
|
1984-10-02 |
1990-11-13 |
Fumiaki Taguchi |
Substance-conjugated complement component c1q
|
|
JPS61271455A
(ja)
|
1985-05-28 |
1986-12-01 |
Olympus Optical Co Ltd |
免疫学的分析方法
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
WO1993003769A1
(en)
|
1991-08-20 |
1993-03-04 |
THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
|
DE614989T1
(de)
|
1993-02-17 |
1995-09-28 |
Morphosys Proteinoptimierung |
Verfahren für in vivo Selektion von Ligandenbindende Proteine.
|
|
ATE304604T1
(de)
|
1993-06-24 |
2005-09-15 |
Frank L Graham |
Adenovirus vektoren für gentherapie
|
|
DE69429816T2
(de)
|
1993-09-01 |
2002-09-19 |
Stichting Sanquin Bloedvoorziening, Amsterdam |
C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
|
|
DE69434594T2
(de)
|
1993-10-25 |
2006-09-21 |
Canji, Inc., San Diego |
Rekombinante adenoviren-vektor und verfahren zur verwendung
|
|
DE69526377T2
(de)
|
1994-12-09 |
2002-11-07 |
Microscience Ltd |
Virulenzgene in der VGC2-Region von Salmonella
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB2325003B
(en)
|
1996-10-17 |
2000-05-10 |
Oxford Biomedica Ltd |
Rectroviral vectors
|
|
GB9622500D0
(en)
|
1996-10-29 |
1997-01-08 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
US6969601B2
(en)
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
JP4437192B2
(ja)
|
1998-02-20 |
2010-03-24 |
タノックス インコーポレイテッド |
補体活性化阻害剤
|
|
US6103526A
(en)
|
1998-10-08 |
2000-08-15 |
Protein Sciences Corporation |
Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
|
|
US6492403B1
(en)
|
1999-02-09 |
2002-12-10 |
3-Dimensional Pharmaceuticals, Inc. |
Methods of treating C1s-mediated diseases and conditions and compositions thereof
|
|
WO2000064327A2
(en)
|
1999-04-26 |
2000-11-02 |
Duke University |
Inhibition of complement action
|
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
|
AU3099801A
(en)
|
2000-01-19 |
2001-07-31 |
Biotransplant Incorporated |
Swine defective for transmission of porcine endogenous retrovirus and uses thereof
|
|
DK1252184T3
(da)
|
2000-01-31 |
2008-02-04 |
Pharming Intellectual Pty Bv |
Human C1-inhibitor produceret i mælk af transgene dyr
|
|
PT1265929E
(pt)
|
2000-03-23 |
2009-10-15 |
Genentech Inc |
Inibidores anti-c2/c2a de activação complementar
|
|
US7071299B2
(en)
|
2000-06-21 |
2006-07-04 |
Zymogenetics, Inc. |
Peptide and polypeptide inhibitors of complement C1s
|
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン，エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
|
JP2004536138A
(ja)
|
2001-07-26 |
2004-12-02 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
認識機能を改善する方法
|
|
AU2002360355B2
(en)
|
2001-11-09 |
2005-07-07 |
Government Of The United States Of America, Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
|
JP2005515782A
(ja)
|
2002-01-11 |
2005-06-02 |
ジーティーシー バイオセラピューティックス インコーポレイテッド |
再構築された胚へ核を移植した後の融合および活性化のための方法およびシステム
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
ES2614274T3
(es)
|
2002-09-06 |
2017-05-30 |
Alexion Pharmaceuticals, Inc. |
Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
|
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
|
US9715692B1
(en)
|
2003-04-11 |
2017-07-25 |
Facebook, Inc. |
System for managing bids for pay-per-click search engines
|
|
WO2004103294A2
(en)
|
2003-05-15 |
2004-12-02 |
Tanox, Inc. |
Methods and compositions for the prevention and treatment of sepsis
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US7923010B2
(en)
|
2003-09-11 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
JP2007512846A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
PT1737891E
(pt)
*
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
WO2005123776A1
(en)
|
2004-06-10 |
2005-12-29 |
Omeros Corporation |
Methods for treating conditions associated with lectin-dependent complement activation
|
|
EP2386315A1
(en)
|
2004-06-10 |
2011-11-16 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
JP2008523083A
(ja)
|
2004-12-08 |
2008-07-03 |
イムノメディクス， インコーポレイテッド |
炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
|
|
ATE450522T1
(de)
|
2005-03-16 |
2009-12-15 |
Janssen Pharmaceutica Nv |
Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
|
|
US8163881B2
(en)
|
2005-05-31 |
2012-04-24 |
The Board Of Regents Of The University Of Texas System |
Immunoglobulin molecules with improved characteristics
|
|
CA2654440C
(en)
|
2005-06-06 |
2013-09-03 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
|
|
EP1908797B1
(en)
|
2005-07-05 |
2012-06-06 |
Kaneka Corporation |
Methacrylic resin composition
|
|
CA2619725C
(en)
|
2005-08-18 |
2016-06-07 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against beta-amyloid peptide
|
|
MX2008004693A
(es)
|
2005-10-21 |
2008-09-03 |
Catalyst Biosciences Inc |
Proteasas modificadas que inhiben la activacion del complemento.
|
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
WO2007070375A2
(en)
|
2005-12-09 |
2007-06-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
SI2380587T1
(en)
|
2005-12-21 |
2018-03-30 |
Pharming Intellectual Property B.V. |
Use of a C1 inhibitor to prevent ischemic reperfusion injury
|
|
FR2897868B1
(fr)
*
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
|
EP2596807B1
(en)
|
2006-03-08 |
2015-12-16 |
Archemix LLC |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
CA2646611A1
(en)
|
2006-03-21 |
2008-05-22 |
Genentech, Inc. |
Combinatorial therapy
|
|
ES2785223T3
(es)
|
2006-06-21 |
2020-10-06 |
Uniqure Ip Bv |
Células de insecto para la producción de vectores de AAV
|
|
KR101503540B1
(ko)
|
2006-09-05 |
2015-03-17 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항체 매개된 신경병증의 치료를 위한 방법과 조성물
|
|
SI3028716T1
(sl)
|
2006-10-10 |
2021-01-29 |
Regenesance B.V. |
Komplementarna inhibicija za izboljšano regeneracijo živcev
|
|
US7858752B2
(en)
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
|
CN101679219B
(zh)
|
2006-12-19 |
2014-08-13 |
港大科桥有限公司 |
合成离子通道
|
|
AU2008214359B2
(en)
|
2007-02-05 |
2014-01-16 |
Apellis Pharmaceuticals, Inc. |
Local complement inhibition for treatment of complement-mediated disorders
|
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
|
ATE543835T1
(de)
|
2007-07-16 |
2012-02-15 |
Genentech Inc |
Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
|
|
NZ582619A
(en)
|
2007-08-03 |
2012-08-31 |
Genentech Inc |
Humanized anti-fgf19 antagonists and methods using same
|
|
WO2009020640A2
(en)
*
|
2007-08-08 |
2009-02-12 |
Swarmcast, Inc. |
Media player plug-in installation techniques
|
|
AU2008345242B2
(en)
|
2007-10-31 |
2014-02-27 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2009121065A2
(en)
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
CA2720682A1
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
CA2726845C
(en)
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
|
US20090324585A1
(en)
|
2008-06-12 |
2009-12-31 |
The Trustees of the Leland Standford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
US20110311550A1
(en)
|
2008-10-24 |
2011-12-22 |
The Scripps Research Institute |
Agents for hcv treatment
|
|
US9447176B2
(en)
|
2008-11-10 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
CN102203610A
(zh)
|
2008-12-01 |
2011-09-28 |
利兰·斯坦福青年大学托管委员会 |
用于检测补体结合性抗体的方法和组合物
|
|
CA2745439C
(en)
*
|
2008-12-03 |
2019-10-15 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
US20100291106A1
(en)
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
KR20120105405A
(ko)
|
2009-06-23 |
2012-09-25 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체 단백질에 결합하는 이중특이적 항체
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
AU2010306581B2
(en)
|
2009-10-16 |
2015-03-19 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
|
|
US8883985B2
(en)
|
2010-02-16 |
2014-11-11 |
National University Corporation Kyoto Institute Of Technology |
Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
|
|
CA2791962A1
(en)
|
2010-03-01 |
2011-09-09 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating degos' disease
|
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
JP6022441B2
(ja)
|
2010-04-30 |
2016-11-09 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗Ｃ５ａ抗体およびその抗体の使用のための方法
|
|
EP2572203B1
(en)
|
2010-05-17 |
2017-10-25 |
The Board of Regents of The University of Texas System |
Determination of antigen-specific antibody sequences in blood circulation
|
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
UY33578A
(es)
|
2010-08-31 |
2012-03-30 |
Sanofi Sa |
PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
|
EP3786185A1
(en)
|
2010-12-06 |
2021-03-03 |
Seagen Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
CA2824279A1
(en)
|
2010-12-22 |
2012-06-28 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life
|
|
CN107638565B
(zh)
|
2011-04-08 |
2021-12-21 |
莱斯特大学 |
用于治疗与masp-2依赖性补体活化相关的状况的方法
|
|
MX361175B
(es)
|
2011-05-04 |
2018-11-29 |
Omeros Corp |
Composiciones para inhibir la activación del complemento dependiente de la masp-2.
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
CN104080474B
(zh)
|
2011-12-22 |
2016-04-27 |
德国杰特贝林生物制品有限公司 |
C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
|
|
JP6081699B2
(ja)
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Ｉｌ−２８ｂの分析方法
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
WO2014066744A2
(en)
|
2012-10-25 |
2014-05-01 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
|
PL2914291T3
(pl)
|
2012-11-02 |
2022-10-03 |
Bioverativ Usa Inc. |
Przeciwciała anty-C1s dopełniacza i ich zastosowania
|
|
BR112015018438A2
(pt)
*
|
2013-01-31 |
2017-07-18 |
Seoul Nat Univ R&Db Foundation |
anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
|
|
US20140294812A1
(en)
|
2013-03-15 |
2014-10-02 |
Xencor, Inc. |
Fc variants that improve fcrn binding and/or increase antibody half-life
|
|
WO2014186622A2
(en)
|
2013-05-15 |
2014-11-20 |
Annexon, Inc. |
Methods of treatment for guillain-barre syndrome
|
|
US9944717B2
(en)
*
|
2013-05-23 |
2018-04-17 |
Broteio Pharma B.V. |
Binding molecules that bind human complement factor C2 and uses thereof
|
|
WO2015006507A1
(en)
*
|
2013-07-09 |
2015-01-15 |
Annexon, Inc. |
Methods of treatment for alzheimer's disease and huntington's disease
|
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
|
KR20170065662A
(ko)
|
2014-10-18 |
2017-06-13 |
화이자 인코포레이티드 |
항-il-7r 항체 조성물
|
|
PL3280440T3
(pl)
*
|
2015-04-06 |
2023-06-19 |
Bioverativ Usa Inc. |
Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
|
|
EP3313417A4
(en)
|
2015-06-26 |
2019-06-12 |
Bioverativ USA Inc. |
METHOD FOR TREATING AUTOIMMUNE AND ALLOIMMUNE DISEASES
|
|
EP4652926A3
(en)
|
2016-10-12 |
2026-03-18 |
Bioverativ USA Inc. |
Anti-c1s antibodies and methods of use thereof
|
|
BR112019018950A2
(pt)
|
2017-03-14 |
2020-04-22 |
Bioverativ Usa Inc. |
métodos para tratamento de doenças e distúrbios mediados por complemento
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CN120209132A
(zh)
|
2018-04-13 |
2025-06-27 |
中外制药株式会社 |
抗补体组分抗体及使用方法
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
IL300376A
(en)
|
2020-08-06 |
2023-04-01 |
Bioverativ Usa Inc |
Inflammatory cytokines and fatigue in subjects with complement-mediated disease
|
|
CN117241828A
(zh)
|
2021-03-31 |
2023-12-15 |
美国比奥维拉迪维股份有限公司 |
减少冷凝集素病患者的手术相关溶血
|
|
TW202417039A
(zh)
|
2022-06-15 |
2024-05-01 |
美商百歐維拉提夫美國公司 |
抗補體ｃ１ｓ抗體調配物
|
|
AU2023286689A1
(en)
|
2022-06-24 |
2025-02-06 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|